StreetInsider.com News Articles

Form SCHEDULE 13D/A PUMA BIOTECHNOLOGY, INC. Filed by: AUERBACH ALAN H

Tue, 06 Oct 2026 21:37:00 -0400

si-local-file:///var/storage/secattach/20261006/27156711.html

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 17:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.

The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017, and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 17:00:00 -0400

Puma Biotechnology starts phase II lung cancer trial with alisertib

Thu, 17 Sep 2026 16:07:36 -0400

Puma Biotechnology, Inc. (NASDAQ: PBYI) has initiated a Phase II clinical trial, ALISCA-Lung2, evaluating alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer, according to a company press release.

The trial, designated PUMA-ALI-4202 (NCT07465757), is a sequential dose escalation study expected to enroll approximately 50 patients whose disease has progressed following platinum-based chemotherapy and immunotherapy. The primary endpoint is safety and tolerability of alisertib when administered with paclitaxel. Secondary endpoints include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival.

Puma also plans to evaluate clinical biomarkers to identify patient

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Thu, 17 Sep 2026 16:07:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The ALISCA®-Lung2 trial is a sequential dose escalation study that will enroll approximately 50 patients with small cell lung cancer who have progressed on or after treatment with platinum-based chemotherapy and immunotherapy.

The primary endpoint of the trial is the safety and tolerability of alisertib when administered with paclitaxel. Secondary endpoints

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Thu, 17 Sep 2026 16:07:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

The primary endpoint of the trial is the safety and tolerability of alisertib when administered with paclitaxel. Secondary endpoints

Form 4 PUMA BIOTECHNOLOGY, INC. For: Sep 14 Filed by: WILSON TROY EDWARD

Wed, 16 Sep 2026 21:14:00 -0400

si-local-file:///var/storage/secattach/20260916/27071600.html

Form 4 PUMA BIOTECHNOLOGY, INC. For: Sep 14 Filed by: Cesano Alessandra

Wed, 16 Sep 2026 21:06:00 -0400

si-local-file:///var/storage/secattach/20260916/27071596.html

Form 144 PUMA BIOTECHNOLOGY, INC. Filed by: Cesano Alessandra

Mon, 14 Sep 2026 12:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27057274.html

Form 144 PUMA BIOTECHNOLOGY, INC. Filed by: WILSON TROY EDWARD

Mon, 14 Sep 2026 12:02:00 -0400

si-local-file:///var/storage/secattach/20260914/27057261.html

Puma Biotechnology (PBYI) PT Raised to $6 at TD Cowen

Fri, 07 Aug 2026 08:52:27 -0400

TD Cowen analyst Marc Frahm raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $6.00 (from $5.00) while maintaining a Hold rating.

Puma Biotech (PBYI) Tops Q2 EPS by 16c

Thu, 06 Aug 2026 17:45:52 -0400

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $56.5 million versus the consensus estimate of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Jun 30

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884993.html

Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Jun 30

Thu, 06 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260806/26884993.html

Form 8-K PUMA BIOTECHNOLOGY, INC. For: Aug 06

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884439.html

Form 8-K PUMA BIOTECHNOLOGY, INC. For: Aug 06

Thu, 06 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260806/26884439.html

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for the second quarter 2026 compared to the second quarter 2025.

Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the second quarter of 2026 was $53.6 million, compared to product revenue, net of $49.2 million in the second quarter of 2025. Product revenue, net in the

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to five new non-executive employees.

The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wed, 05 Aug 2026 17:00:00 -0400

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at